SYN-004 (RIBAXAMASE)
| Source | SynBio Database www.syntheticbiologics.com/index.php?s=43&item=101 |
|---|---|
| Organization | Synthetic Biologics |
| Market status | Under Development |
| Industry | Health |
| Value chain stage | Finished Product |
| Intended consumer | Commercial |
| Production process | Closed Production |
| Business models | B2B |
| Product categories | Medical Treatment |
| Biotech components | Microbe |
| Organization type(s) | Public Company |
| Funding types | Shareholder Investment |
| Known funding amount | $12,467,000 USD |
| Country of production | USA |
| Country of distribution | USA |
| Trading symbol | SYN |
| Trading exchange | NYSEMKT |
| Notes | Minimal information available -- this tech is mentioned in news releases but is not listed on the product pipeline. |